Rajakariar Kevin, Buntine Paul, Ghaly Andrew, Zhu Zheng Cheng, Abeygunawardana Vihangi, Visakhamoorthy Sarah, Owen Patrick J, Tham Shaun, Hackett Liam, Roberts Louise, Sajeev Jithin K, Jones Nicholas, Teh Andrew W
Department of Cardiology, Eastern Health, Melbourne, Victoria, Australia.
Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
Mayo Clin Proc Digit Health. 2024 Feb 26;2(1):152-158. doi: 10.1016/j.mcpdig.2024.02.001. eCollection 2024 Mar.
To assess the ability of 2 commercially available smartwatches to accurately detect clinically significant hypoxia in patients hospitalized with coronavirus-19 (COVID-19).
A prospective multicenter validation study was performed from November 1, 2021, to August 31, 2022, assessing the Apple Watch Series 7 and Withings ScanWatch inbuilt pulse oximetry, against simultaneous ward-based oximetry as the reference standard. Patients hospitalized with active COVID-19 infection not requiring intensive care admission were recruited.
A total of 750 smartwatch pulse oximetry measurements and 400 ward oximetry readings were successfully obtained from 200 patients (male 54%, age 66±18 years). For the detection of clinically significant hypoxia, the Apple Watch had a sensitivity and specificity of 34.8% and 97.5%, respectively with a positive predictive value of 78.1% and negative predictive value of 85.6%. The Withings ScanWatch had a sensitivity and specificity of 68.5% and 80.8%, respectively with a positive predictive value of 44.7% and negative predictive value of 91.9%. The overall accuracy was 84.9% for the Apple Watch and 78.5% for the Withings ScanWatch. The Spearman rank correlation coefficients reported a moderate correlation to ward-based photoplethysmography (Apple: r=0.61; Withings: r=0.51, both <.01).
Although smartwatches are able to provide SpO readings, their overall accuracy may not be sufficient to replace the standard photoplethysmography technology in detecting hypoxia in patients with COVID-19.
评估两款市售智能手表准确检测新型冠状病毒肺炎（COVID-19）住院患者临床上显著低氧血症的能力。
于2021年11月1日至2022年8月31日进行了一项前瞻性多中心验证研究，以苹果手表Series 7和Withings ScanWatch内置的脉搏血氧饱和度测定法为研究对象，同时以病房内的血氧饱和度测定法作为参考标准。招募了因COVID-19感染住院且无需入住重症监护病房的患者。
成功从200名患者（男性占54%，年龄66±18岁）处获得了750次智能手表脉搏血氧饱和度测量值和400次病房血氧饱和度读数。对于临床上显著低氧血症的检测，苹果手表的灵敏度和特异性分别为34.8%和97.5%，阳性预测值为78.1%，阴性预测值为85.6%。Withings ScanWatch的灵敏度和特异性分别为68.5%和80.8%，阳性预测值为44.7%，阴性预测值为91.9%。苹果手表的总体准确率为84.9%，Withings ScanWatch为78.5%。Spearman等级相关系数显示与病房内光电容积描记法呈中度相关（苹果手表：r = 0.61；Withings：r = 0.51，均P<0.01）。
尽管智能手表能够提供血氧饱和度读数，但其总体准确率可能不足以替代标准光电容积描记法技术来检测COVID-19患者的低氧血症。
